"name","instanceType","uuid:ID","label","description","id","rationale"
"Study Design 1","StudyDesign","401747c4-d596-4051-8258-229bfbda5372","","The main design for the study","StudyDesign_1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated."
